Anthropic Unveils Claude Science and Its Own Drug Lab: The AI Company That Wants to Make Medicine

An AI company opening wet labs to hunt for new drugs. That sentence would have sounded absurd two years ago. Anthropic just made it real on June 30 in San Francisco, unveiling Claude Science alongside an internal drug discovery program.

Claude Science: an AI workbench built for pharma researchers

Claude Science is a beta research environment that runs on Linux and macOS. The tool integrates more than 60 scientific functions across genomics, proteomics, structural biology, and cheminformatics.

Early customers include Novo Nordisk and the Allen Institute. Anthropic is also offering up to $30,000 in credits for 50 research projects, with applications closing July 15.

Anthropic's own drug discovery lab targets neglected diseases

Here's where things get bold. Eric Kauderer-Abrams, Anthropic's head of life sciences, announced the company will run its own drug discovery program focused on diseases that traditional pharma ignores because the economics don't add up.

The reasoning? You can't build great scientific tools from the sidelines. As Jonah Cool, Anthropic's head of life sciences partnerships, told STAT: you can't advance a tool like Claude Science if you're not engaged in preclinical work yourself. Anthropic laid the groundwork back in April by acquiring Coefficient Bio for roughly $400 million, absorbing a team of former Genentech computational researchers.

A three-way race for AI-driven drug discovery

Anthropic enters a crowded ring. OpenAI shipped GPT-Rosalind in April, its first purpose-built life sciences model. Google DeepMind's Isomorphic Labs holds $3 billion in milestone partnerships with Eli Lilly and Novartis, with AI-designed drug candidates nearing clinical trials.

What sets Anthropic apart: as a public benefit company, it can chase programs that pure-profit pharma firms won't touch. Novartis CEO Vas Narasimhan joined Anthropic's board this year, a signal that Big Pharma takes this ambition seriously.

No miracle molecule yet, but a clear direction

Let's keep perspective. No AI-discovered drug has completed a large-scale clinical trial to date. Anthropic hasn't said whether it would commercialize any candidates or license them. But the direction of travel is unmistakable: the biggest AI labs are no longer just selling picks and shovels. They want to dig for gold themselves.